Pharmaceutical
Medical Devices
Technology
Daiichi Sankyo
$49.419876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$49.41
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$1.48 (-2.90%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell Daiichi Sankyo and other stocks, options, ETFs, and crypto commission-free!
About
Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Daiichi Sankyo Group and Ranbaxy Group. Read More The Daiichi Sankyo Group segment comprises of Daiichi Sankyo Co., Ltd. and its subsidiaries. The Ranbaxy Group segment includes its core company, Ranbaxy Laboratories Ltd. Both group segments deal with business activities in prescription drugs and general pharmaceutical products. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan. DSNKY is listed on the Pink Current market tier. OTC market data is provided by OTC Markets Group, Inc (otcmarkets.com).
Employees
14,446
Headquarters
Tokyo, Tokyo
Founded
2005
Market Cap
32.97B
Price-Earnings Ratio
38.08
Dividend Yield
1.60
Average Volume
15.95K
High Today
$50.89
Low Today
$49.33
Open Price
$50.89
Volume
5.97K
52 Week High
$53.06
52 Week Low
$30.00
Collections
Pharmaceutical
Medical Devices
Technology
Health
Medical
Asia (Non-China)
Asia
News
ReutersMay 14
FDA advisory panel votes against Daiichi Sankyo's cancer treatment
(Reuters) - Independent experts on an FDA advisory panel on Tuesday voted against Daiichi Sankyo Co Ltdâs treatment for adults with a type of acute myeloid leukemia.
Seeking AlphaMay 13
Daiichi Sankyo launches MINNEBRO tablets in Japan
Exelixis' (NASDAQ:EXEL) partner Daiichi Sankyo (OTCPK:DSNKY) has launched MINNEBRO (esaxerenone) tablets as a treatment for patients with hypertension in Japan.
Yahoo FinanceMay 13
Exelixisâ Collaborator Daiichi Sankyo Launches MINNEBROÂŽ (Esaxerenone) Tablets in Japan
ALAMEDA, Calif.--(BUSINESS WIRE)-- -- First commercial sale triggers $20 million milestone payment to Exelixis -- Exelixis, Inc. (EXEL) today announced its partner Daiichi Sankyo Company, Limited (âDaiichi Sankyoâ) has launched MINNEBROÂŽ (esaxerenone) tablets as a treatment for patients with hypertension in Japan. With Daiichi Sankyoâs first commercial sale of MINNEBRO, Exelixis will receive an associated $20 million milestone payment from Daiichi Sankyo under the terms of the companiesâ collaboration agr...
Price Paid on Robinhood
16% Higher
Right Now
52 Week Low
$30.00
Average Price Paid
$42.73
52 Week High
$53.06